In MB transgenic mice harbouring the SMO-W539L mutation, ABT-199 significantly inhibited tumour growth, whereas GDC-0449 showed no effect, suggesting that ABT-199 can overcome resistance to current SMO inhibitors caused by SMO mutations [173]. This evidence concerns the gene SMO and neoplasm.